India is called the pharmacy of the world as it is the largest supplier of low-cost generics, vaccines, and affordable medicines. Further, Covid-19 highlighted the need for expanding the healthcare infrastructure in the country. Under Atmanirbhar Bharat, the government has come up with a PLI scheme for promoting India’s manufacturing and exports in the pharma sector.

This smallcase invests in Nifty Healthcare and Nifty Pharma ETFs which represent companies in pharma, hospitals, diagnostics, and healthcare.